Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy
In the register
The register attaches this trial to CG 428 (Legacy Healthcare), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Legacy Healthcare SA
- Participants (registry)
- 40
- Start
- October 2016
- Primary completion
- July 2018
- Study completion
- March 2019
- Last registry update
- August 2019
- Countries
- Switzerland
Conditions studied: Alopecia
Interventions: CG 428 cutaneous solution, Placebo cutaneous solution
Other trials of CG 428
- NCT02605629Completed
EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors
- NCT02986412Completed
A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.